Acadian Asset Management LLC Liquidia Corp Transaction History

Acadian Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$3.37 - $7.55 $394,445 - $883,697	-117,046 Reduced 45.16%	142,156 $620,000
Q1 2022 May 12, 2022	BUY	$5.14 - $7.38 $686,626 - $985,857	133,585 Added 106.34%	259,202 $1.86 Million
Q4 2021 Feb 10, 2022	BUY	$2.71 - $5.17 $340,422 - $649,439	125,617 New	125,617 $610,000
Q3 2021 Nov 12, 2021	SELL	$2.28 - $2.95 $26,235 - $33,945	-11,507 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$2.51 - $3.11 $28,882 - $35,786	11,507 New	11,507 $33,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.